Multiple Sclerosis

RHB-104 is a proprietary, orally administered antibiotic combination therapy, with intracellular, antimycobacterial and anti- inflammatory properties.

RHB-104 has is targeting several indications, including Multiple Sclerosis, an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system that exhibits characteristics of both infectious and autoimmune pathology.

RHB-104 is a multifaceted drug that in addition to bactericidal properties against intracellular infections, has potentially distinct mechanisms of action that include both anti-inflammation and neuroprotection.

RedHill has successfully completed a Phase 2a proof of concept clinical study of RHB-104 as an add-on therapy to interferon beta-1a in patients with Relapsing Remitting Multiple Sclerosis (the CEASE MS study). The study demonstrated positive safety and clinical signals supporting therapeutic potential of RHB-104 in multiple sclerosis. Read more about the study results here.

RHB 104